Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiangqin Jiere Granules (香芩解热颗粒) is an innovative Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical. Formulated as oral granules, it is primarily indicated for the treatment of fever and symptoms associated with respiratory diseases, such as the common cold or influenza. The formulation is designed to clear heat and resolve toxins according to TCM principles. As of the latest clinical development updates, the drug has been approved for clinical trials and is currently in Phase 3 research in China, positioning it as a late-stage candidate in the company's respiratory pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiangqin Jiere Granules.